| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 464 | 2017 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 225 | 2017 |
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy S Champiat, C Ferté, S Lebel-Binay, A Eggermont, JC Soria Oncoimmunology 3 (1), e27817, 2014 | 170 | 2014 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 162 | 2018 |
| Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology EJ Limkin, R Sun, L Dercle, EI Zacharaki, C Robert, S Reuzé, ... Annals of Oncology 28 (6), 1191-1206, 2017 | 137 | 2017 |
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 134 | 2018 |
| Molecular circuits of solid tumors: prognostic and predictive tools for bedside use C Ferté, F André, JC Soria Nature reviews Clinical oncology 7 (7), 367, 2010 | 107 | 2010 |
| Hyperprogressive disease: recognizing a novel pattern to improve patient management S Champiat, R Ferrara, C Massard, B Besse, A Marabelle, JC Soria, ... Nature Reviews Clinical Oncology 15 (12), 748-762, 2018 | 86 | 2018 |
| Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial C Jovelet, E Ileana, MC Le Deley, N Motté, S Rosellini, A Romero, ... Clinical Cancer Research 22 (12), 2960-2968, 2016 | 74 | 2016 |
| Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials C Ferté, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ... Clinical Cancer Research 20 (1), 246-252, 2014 | 70 | 2014 |
| Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET … C Ferte, S Koscielny, L Albiges, L Rocher, JC Soria, R Iacovelli, Y Loriot, ... European urology 65 (4), 713-720, 2014 | 54 | 2014 |
| Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues C Ferté, A Paci, M Zizi, DB Gonzales, A Goubar, C Gomez-Roca, ... European Journal of Cancer 47 (15), 2249-2255, 2011 | 51 | 2011 |
| Tumour growth rates and RECIST criteria in early drug development C Gomez-Roca, S Koscielny, V Ribrag, C Dromain, I Marzouk, F Bidault, ... European journal of cancer 47 (17), 2512-2516, 2011 | 49 | 2011 |
| Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review JE Bibault, I Fumagalli, C Ferté, C Chargari, JC Soria, E Deutsch Cancer and Metastasis Reviews 32 (3-4), 479-492, 2013 | 39 | 2013 |
| Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial L Verlingue, D Malka, A Allorant, C Massard, C Ferté, L Lacroix, ... European Journal of Cancer 87, 122-130, 2017 | 38 | 2017 |
| Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons A Hollebecque, D Malka, C Ferté, M Ducreux, V Boige European Journal of Cancer 51 (3), 327-339, 2015 | 36 | 2015 |
| Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology C Ferté, AD Trister, E Huang, BM Bot, J Guinney, F Commo, S Sieberts, ... Clinical Cancer Research 19 (16), 4315-4325, 2013 | 36 | 2013 |
| IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy C Ferté, Y Loriot, C Clémenson, F Commo, A Gombos, JE Bibault, ... Molecular cancer therapeutics 12 (7), 1213-1222, 2013 | 34 | 2013 |
| Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy … D Ou, P Blanchard, S Rosellini, A Levy, F Nguyen, RTH Leijenaar, ... Oral oncology 71, 150-155, 2017 | 31 | 2017 |
| Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence L Dercle, S Ammari, M Bateson, PB Durand, E Haspinger, C Massard, ... Scientific reports 7 (1), 1-10, 2017 | 30 | 2017 |
Jean-Charles SoriaDrug Development Department, Gustave RoussyAdresse e-mail validée de gustaveroussy.fr
